Xalud Therapeutics

Xalud Therapeutics is pioneering a non-viral gene therapy platform targeting chronic inflammation, a root cause of many prevalent diseases. Its lead candidate, XT-150, delivers a modified IL-10 cytokine via plasmid DNA and is being evaluated in multiple indications, including osteoarthritis and facet joint syndrome, with a completed Phase 2b trial. The company's technology aims to expand gene therapy access beyond rare monogenic conditions to address widespread chronic inflammatory and neurodegenerative diseases with high unmet need. Xalud represents a novel approach by aiming to restore immune balance locally with a potentially durable and redosable therapy.

Proprietary non-viral plasmid DNA (pDNA) gene therapy delivery platform designed for local, durable, and safe expression of therapeutic transgenes, with potential for redosing. It is non-immunogenic and non-integrating.

Xalud competes in the broad anti-inflammatory space against large pharma's NSAIDs, steroids, and biologic drugs (e.g., anti-TNFs). In gene therapy, it differentiates from viral-vector approaches. Its direct competitors are other companies developing disease-modifying OA drugs (DMOADs) and novel pain therapies, as well as biotechs targeting IL-10 or other immunomodulatory pathways with different modalities.